Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04411069
Other study ID # NP 1336/18
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 20, 2019
Est. completion date March 20, 2021

Study information

Verified date May 2021
Source Instituto do Cancer do Estado de São Paulo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Previous history of nausea and vomiting induced by prior chemotherapy still not included as predictive factor of postoperative nausea and vomiting, although has been demonstrated that has influence in postoperative outcome. The project aims to evaluate the efficacy of a simplified algorithm in prevention postoperative nausea and vomiting , with pacients with previous history of nausea and vomiting induced by prior chemotherapy, submitted to medium or large surgery.


Description:

Quasi-experimental study, with evaluation after the application of a specific postoperative nausea and vomiting prevention algorithm for cancer patients. The study will be carried out in 2 phases: Phase 1: Team training. In this phase, a protocol was established for PONV prophylaxis, using two questions: 1. Patient undergoing chemotherapy before surgery; 2. Patient presented chemotherapy induced nausea and vomiting (CINV). If the answer is yes to both questions, the anesthetist administers 3 antiemetics (4mg dexametasone, 4mg ondansetron and 0,625mg droperidol). If the answer is no to one of the questions, the anesthetist administers 2 antiemetics (4mg dexametasone and 4mg ondansetron); In this phase, educational measures will be implemented by team meetings and individual approach of all anesthesiologists at ICESP to present the study project and the algorithm. A summary of the the study will be sent daily through the social network Whats AppĀ®. The number of patients was calculated taking into account adherence to the new prophylaxis protocol for post-operative nausea and vomiting. If we consider an alpha error of 5% and test power of 80%, to have a NVPO reduction of 41% (current overall incidence) to 25% (incidence after protocol adherence) in high-risk patients, we need to study 270 patients (135 each group adherence and non-adherence to the protocol). Phase 2: Post-training assessment. In the second phase of the study, after the end of the dissemination of the protocol among doctors, the patients will be evaluated on the first postoperative day. The following variables were analyzed: sex, race, age, body mass index, general state of American Society of Anesthesiologist, Apfel scale, type of surgery and anesthesia, use and type of opioids, history of chemotherapy induced nausea and vomiting, type of antiemetics used in the operating room and in the first postoperative day, duration of anesthesia and surgery and nausea and vomiting in 6 and 24 hours after surgery.


Recruitment information / eligibility

Status Completed
Enrollment 270
Est. completion date March 20, 2021
Est. primary completion date March 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients who underwent medium to large surgery Exclusion Criteria: - Patients who are unable to communicate (orotracheal intubation after the surgery, confusion or agitation) or understand the Portuguese language; - Insulin dependent patients - Patients who underwent emergency surgery and neurosurgery - Pacients who had an increased QT interval on the electrocardiogram - History of allergy to dexametasone, ondansetron or droperidol - Refusal to participate

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Droperidol
Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol

Locations

Country Name City State
Brazil Cancer Institute of the State of Sao Paulo - ICESP Sao Paulo São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Instituto do Cancer do Estado de São Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary postoperative nausea and vomiting record of any episode of nausea and or vomiting in the 24 postoperative hours from 0 to 24 postoperative hours
Secondary Changing in the institutional protocol number of patients with chemotherapy-induced nausea and vomiting that received 3 antiemetics in the operating room from the begining to the study to the end of the study (2 years)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03639012 - Outcomes of Carbohydrate Loading Paediatric Patients Preoperatively for Tonsillectomy and Adenoidectomy N/A
Not yet recruiting NCT01389570 - Postoperative Nausea/Vomiting and Acupressure Phase 2
Completed NCT00830089 - Trial of a Transversus Abdominis Plane (TAP) Block in Laparoscopic Colorectal Surgery N/A
Terminated NCT05112575 - Evaluation of Patient Stress Level Caused by Radiological Investigations in Early Postoperative Phase After Craniotomy
Completed NCT04759079 - The Effects of Acupuncture Against Postoperative Nausea and Vomit After Laparoscopic Cholecystectomy N/A
Active, not recruiting NCT03712891 - Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU N/A
Completed NCT01834898 - Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery N/A
Completed NCT03631004 - Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients Phase 2/Phase 3
Completed NCT05618236 - Sugammadex and Neostigmine in Pediatric Patients
Not yet recruiting NCT05632224 - Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery Phase 4
Completed NCT01020903 - Aprepitant for Post-operative Nausea N/A
Completed NCT00793663 - Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia Phase 4
Completed NCT03503292 - Pharmacogenomics and Post-Operative Nausea and Vomiting Phase 4
Completed NCT05841693 - Quality of Recovery in Parturients Consumed Preoperative Carbohydrate Fluid for Elective Cesarean Delivery Phase 4
Completed NCT04742660 - The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting N/A
Completed NCT03100669 - Implementing a Postoperative MIRP (Minimally Invasive Repair of Pectus) Program Via Tele-monitoring
Terminated NCT02765750 - Postoperative Outcomes After Positive Intraoperative Messages N/A
Terminated NCT01798316 - IV Acetaminophen for Postoperative Analgesia Phase 4
Completed NCT03387956 - Intrathecal Atropine to Prevent Postoperative Nausea and Vomiting N/A
Completed NCT04718727 - Olanzapine for the Prevention of Postoperative Nausea and Vomiting Phase 1/Phase 2